Monaco Asset Management SAM Increases Stock Holdings in Novavax, Inc. $NVAX

Monaco Asset Management SAM boosted its holdings in Novavax, Inc. (NASDAQ:NVAX) by 73.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 400,000 shares of the biopharmaceutical company’s stock after purchasing an additional 170,000 shares during the quarter. Monaco Asset Management SAM owned approximately 0.25% of Novavax worth $3,468,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Personalized Indexing Management LLC increased its stake in shares of Novavax by 11.0% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 12,755 shares of the biopharmaceutical company’s stock valued at $111,000 after acquiring an additional 1,268 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Novavax by 2.3% in the second quarter. The Manufacturers Life Insurance Company now owns 78,048 shares of the biopharmaceutical company’s stock valued at $492,000 after purchasing an additional 1,718 shares during the period. SBI Securities Co. Ltd. increased its position in Novavax by 5.5% during the second quarter. SBI Securities Co. Ltd. now owns 34,095 shares of the biopharmaceutical company’s stock worth $215,000 after purchasing an additional 1,766 shares during the last quarter. E Fund Management Co. Ltd. increased its position in Novavax by 9.0% during the second quarter. E Fund Management Co. Ltd. now owns 28,280 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 2,326 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Novavax by 2.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company’s stock valued at $678,000 after purchasing an additional 2,750 shares during the last quarter. 53.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Cantor Fitzgerald began coverage on Novavax in a research report on Friday, October 24th. They issued an “overweight” rating and a $18.00 target price on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Novavax in a research report on Monday, December 29th. Wall Street Zen cut shares of Novavax from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. B. Riley Financial reissued a “buy” rating and issued a $16.00 price objective (down previously from $18.00) on shares of Novavax in a research report on Monday, November 10th. Finally, BTIG Research reissued a “buy” rating and issued a $19.00 target price on shares of Novavax in a research note on Tuesday, January 20th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, Novavax currently has an average rating of “Hold” and an average target price of $11.25.

Novavax Trading Down 0.3%

NVAX opened at $9.20 on Friday. The firm’s 50 day moving average is $8.01 and its 200-day moving average is $7.96. Novavax, Inc. has a 52-week low of $5.01 and a 52-week high of $10.64. The company has a quick ratio of 2.24, a current ratio of 2.27 and a debt-to-equity ratio of 5.93. The firm has a market capitalization of $1.50 billion, a P/E ratio of 5.14 and a beta of 2.58.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.